A tale of two factors: What determines the rate of progression in Huntington's disease? A longitudinal MRI study

Over the past several years, increased attention has been devoted to understanding regionally selective brain changes that occur in Huntington's disease and their relationships to phenotypic variability. Clinical progression is also heterogeneous, and although CAG repeat length influences age of onset, its role, if any, in progression has been less clear. We evaluated progression in Huntington's disease using a novel longitudinal magnetic resonance imaging analysis. Our hypothesis was that the rate of brain atrophy is influenced by the age of onset of Huntington's disease. We scanned 22 patients with Huntington's disease at approximately 1‐year intervals; individuals were divided into 1 of 3 groups, determined by the relative age of onset. We found significant differences in the rates of atrophy of cortex, white matter, and subcortical structures; patients who developed symptoms earlier demonstrated the most rapid rates of atrophy compared with those who developed symptoms during middle age or more advanced age. Rates of cortical atrophy were topologically variable, with the most rapid changes occurring in sensorimotor, posterior frontal, and portions of the parietal cortex. There were no significant differences in the rates of atrophy in basal ganglia structures. Although both CAG repeat length and age influenced the rate of change in some regions, there was no significant correlation in many regions. Rates of regional brain atrophy seem to be influenced by the age of onset of Huntington's disease symptoms and are only partially explained by CAG repeat length. These findings suggest that other genetic, epigenetic, and environmental factors play important roles in neurodegeneration in Huntington's disease. © 2011 Movement Disorder Society

[1]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[2]  Anders M. Dale,et al.  Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer , 2006, NeuroImage.

[3]  M. Beal,et al.  Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients , 1995, Neurology.

[4]  Arne Klungland,et al.  OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells , 2007, Nature.

[5]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Oorschot,et al.  Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. , 2010, Brain : a journal of neurology.

[7]  G. Pearlson,et al.  Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.

[8]  A. Hannan,et al.  Genetic and environmental factors in the pathogenesis of Huntington’s disease , 2004, Neurogenetics.

[9]  Nick C Fox,et al.  Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease , 2009, Journal of Neurology.

[10]  M. MacDonald,et al.  Trinucleotide repeat length and progression of illness in Huntington's disease. , 1994, Journal of medical genetics.

[11]  P. Mecocci,et al.  Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex , 1999, Neuroscience Letters.

[12]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[13]  Anders M. Dale,et al.  Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex , 2001, IEEE Transactions on Medical Imaging.

[14]  Bruce Fischl,et al.  Highly accurate inverse consistent registration: A robust approach , 2010, NeuroImage.

[15]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.

[16]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[17]  A. Dale,et al.  Thinning of the cerebral cortex in aging. , 2004, Cerebral cortex.

[18]  E. Siemers,et al.  Rate of functional decline in Huntington’s disease , 2000, Neurology.

[19]  D. Berry,et al.  Symmetrized Percent Change for Treatment Comparisons , 2006 .

[20]  Radu Constantinescu,et al.  The relationship between CAG repeat length and clinical progression in Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[21]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[22]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[23]  Peng Yu,et al.  Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical “disconnection” , 2010, NeuroImage.

[24]  J. Brandt,et al.  The association of CAG repeat length with clinical progression in Huntington disease , 2006, Neurology.

[25]  A. Dale,et al.  One-Year Brain Atrophy Evident in Healthy Aging , 2009, The Journal of Neuroscience.